Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel, Gemcitabine, and Cisplatin for High-Risk Intrahepatic Cholangiocarcinoma
NCT03579771Phase 2Completed
- Sponsor
- Emory University
- Start
- Sep 2018
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel in intrahepatic cholangiocarcinoma (ICC), sponsored by Emory University. Primary endpoint: Number of Participants Who Completed All Preoperative and Operative Therapy at 12 weeks. Started Sep 2018; status: completed.
02
Drugs
paclitaxel
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT03579771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03579771.